Sigbjørn Smeland

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

Sigbjørn Smeland, Stefan Bielack, Jeremy Whelan et al. · European Journal of Cancer · 2019 · 700 citations · Full text

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

Neyssa Marina, Sigbjørn Smeland, Stefan Bielack et al. · The Lancet Oncology · 2016 · 511 citations · Full text

Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups

Stefano Ferrari, Sigbjørn Smeland, Mario Mercuri et al. · Journal of Clinical Oncology · 2005 · 432 citations

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

Stefan Bielack, Sigbjørn Smeland, Jeremy Whelan et al. · Journal of Clinical Oncology · 2015 · 412 citations · Full text

EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment

Jeremy Whelan, Stefan Bielack, Neyssa Marina et al. · Annals of Oncology · 2014 · 321 citations · Full text